RAPT Therapeutics, Inc. announced that positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD) were presented at the European Academy of Dermatology and Venereology (EADV) Congress by Robert Bissonnette, M.D., FRCPC. Dr. Bissonnette is a board-certified dermatologist and currently serves as president of the board of directors of the International Eczema Council. He is also chief executive officer and medical director of Innovaderm Research Inc., a contract research organization that specializes in conducting clinical studies in dermatology. The Phase 1b trial results demonstrated that at Day 29 after end of treatment, clear benefit over placebo was observed on Eczema Area and Severity Index (EASI) score, EASI-50, vIGA 0/1 (clear or almost clear skin), body surface area (BSA), and pruritis NRS-3 and 4 (3 and 4 point reduction on the numerical rating scale for itch). By the end of study, including the two-week follow-up period (Day 43), RPT193 demonstrated continued improvement in the EASI, EASI-50, EASI-75, EASI-90, vIGA 0/1, and BSA. In a post-hoc statistical analysis comparing RPT193-treated patients to placebo-treated patients, statistically significant improvements in EASI, EASI-50 and BSA were observed at Day 43. RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity.